Ms. Maryam Marissen reports

PANGENOMIC HEALTH SIGNS LETTER OF INTENT WITH CRESCITA CAPITAL FOR $5 MILLION EQUITY DRAWDOWN FACILITY

Pangenomic Health Inc. has entered into a non-binding letter of intent with Crescita Capital LLC for a $5-million equity drawdown facility.

Under the proposed non-revolving equity drawdown facility, Pangenomic Health will have three years to utilize the $5-million for general working capital purposes and strategic acquisitions. Pangenomic Health can draw down funds from the equity drawdown facility from time to time during the three-year term at Pangenomic Health's discretion by providing a notice to Crescita Capital. In consideration for advances made by Crescita Capital under the equity drawdown facility, Pangenomic Health will allot and issue units to Crescita Capital at an issue price equal to the greater of 85 per cent of the average closing bid price of Pangenomic Health's Class A common shares on the Canadian Securities Exchange during the 10 trading days immediately prior to the closing date of each drawdown and the minimum issue price permitted by the CSE. Each unit issued under the equity drawdown facility will comprise one common share and one-half of one common share purchase warrant. Each warrant will be exercisable for three years from the date of issue at an exercise price equal to the greater of 125 per cent of the issue price and the minimum exercise price permitted by the CSE.

Upon the execution of a definitive agreement for the equity drawdown facility, Pangenomic Health will be required to pay a commitment fee to Crescita Capital equal to 6 per cent of the total commitment ($300,000), payable in cash or common shares at a deemed price equal to the greater of four cents per common share and the minimum price permitted by the CSE. Pangenomic Health will also be required to pay the legal fees of Crescita Capital up to a maximum of $26,000.

The proposed equity drawdown facility is subject to the execution of a definitive agreement and the customary conditions precedent for transactions of this nature, including the approval of the CSE if required under its rules and policies.

"We are very excited to work with Crescita Capital," said Maryam Marissen, chief executive officer of Pangenomic Health. "We believe that access to their innovative equity financing platform and international business network will help grow our business by accelerating development and marketing initiatives for our MUJN, Nara and Mindleap products."

About Pangenomic Health Inc.

Pangenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments.

We seek Safe Harbor.